Healio: Two studies provide further positive outcomes for empagliflozin in HF

October 8, 2020

Among patients with heart failure, empagliflozin lowered diastolic pulmonary artery pressure and was effective at reducing cardiovascular death and heart failure hospitalizations regardless of sacubitril/valsartan use, researchers reported.

Dr. Mikhail Kosiborod, vice president of research at Saint Luke's Health System, detailed the results of the EMBRACE-HF study looking at the impact of empagliflozin in patients with heart failure and higher diastolic pulmonary artery pressure.

Read the full Healio article: Two studies provide further positive outcomes for empagliflozin in HF

Related Content

Healio: No difference in sustained health status improvements in TAVR vs. surgical AVR
Patients who had TAVR had similar health status after five years with those who had surgical AVR, according to a new study by Dr. Suzanne Arnold.
TCTMD: Pesco-Mediterranean Diet should be the gold standard, says JACC review
A Pesco-Mediterranean Diet with fish and intermittent fasting is optimal for heart health, according to a new review by Dr. James O'Keefe.
Healio: PET may be beneficial to guide revascularization strategy for CAD
PET perfusion and flow assessment may guide revascularization strategies for patients with carotid artery disease (CAD), according to a presentation at the Scientific Session and Exhibition of the American Society of Nuclear Cardiology.